Heptar

Heptar is an anticoagulant biologic developed by Eurofarma Laboratorios S.A., containing bovine-derived unfractionated sodium heparin. It is specifically indicated for the prevention of clot formation in the extracorporeal circuit during hemodialysis in patients with chronic kidney disease (CKD) or end-stage renal disease. As an unfractionated heparin, Heptar acts by binding to and accelerating the activity of antithrombin III, which subsequently inactivates thrombin (Factor IIa) and Factor Xa, thereby inhibiting the coagulation cascade. The drug is formulated as an injectable solution at a concentration of 5000 IU/mL. Heptar was evaluated in a Phase 3, randomized, double-blind, non-inferiority clinical trial comparing its safety and efficacy to the reference product Liquemine (Roche), demonstrating its effectiveness in maintaining circuit patency during consecutive hemodialysis sessions.

Brand names

Heptar

Other names

Bovine sodium heparinHeparina sódica bovina